Home / Stocks / ARQT

ARQT insider trading

Arcutis Biotherapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
9
Bought · 24 mo
$421k
Buys · last 90 days
0 · $0
Most recent buy
2025-06-17

Recent insider filings

FiledInsiderTypeSharesPriceValue
2025-11-24Watanabe Todd
See Remarks
Sold48,945$30.36$1.5M
2025-10-30Watanabe Todd
See Remarks
Sold40,000$25.03$1.0M
2025-06-17Heron Patrick J
Director
Bought2,646$13.08$35k
2025-06-06Heron Patrick J
Director
Bought2,268$13.34$30k
2025-05-23Heron Patrick J
Director
Bought5,040$13.65$69k
2025-05-19Heron Patrick J
Director
Bought2,520$13.62$34k
2025-05-15Heron Patrick J
Director
Bought8,674$13.76$119k
2025-05-13Heron Patrick J
Director
Bought6,300$13.60$86k
2024-12-03Matsuda Masaru
See Remarks
Bought5,657$3.28$19k
2024-12-03Watanabe Todd Franklin
See Remarks
Bought6,038$3.52$21k
2024-12-03Edwards Larry Todd
See Remarks
Bought1,093$7.11$8k

Most active insider buyers

InsiderRoleBuysTotal bought
Heron Patrick JDirector6$373k
Watanabe Todd FranklinSee Remarks1$21k
Matsuda MasaruSee Remarks1$19k
Edwards Larry ToddSee Remarks1$8k

See ARQT on the chart

Every insider buy and sell for ARQT plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.